title: Erythema multiforme major following treatment with infliximab.
abstract: BACKGROUND
  The growth in the use of anti-tumor necrosis factor α (TNF-α) agents for treatment of inflammatory conditions has led to increased recognition of the side effects associated with this class of drugs.
  
  
  METHODS
  We report a case of a patient who developed erythema multiforme (EM) major with characteristic oral and cutaneous lesions following treatment with the anti-TNF-α medication infliximab therapy for Crohn's disease (CD).
  
  
  CONCLUSIONS
  To our knowledge, this is the first reported case of infliximab-induced EM secondary to the treatment of CD. It is important for dental clinicians evaluating patients using anti-TNF-α agents to be aware of this possible complication.
authors.affiliation: National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland 20892, USA. dean.edwards@nih.gov
authors.forename: Dean
authors.initials: D
authors.lastname: Edwards
authors.forename: Eli
authors.initials: E
authors.lastname: Boritz
authors.forename: Edward W
authors.initials: EW
authors.lastname: Cowen
authors.forename: Ronald S
authors.initials: RS
authors.lastname: Brown
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D003424:Crohn Disease / Q000188:drug therapy*; D004892:Erythema Multiforme / Q000139:chemically induced*; D005260:Female; D005765:Gastrointestinal Agents / Q000009:adverse effects*; D006801:Humans; D000069285:Infliximab; D019226:Oral Ulcer / Q000139:chemically induced*
chemical_list: D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D000069285:Infliximab